ImmunityBio posts strong Q3 sales and FDA label expansion but misses earnings expectations, sending stock sharply lower
ImmunityBio reported third‑quarter 2026 product revenue of about $48.7‑$48.84 million, a 53% year‑over‑year increase, and nine‑month revenue of $143.6 million, up 92%. The FDA broadened ANKTIVA’s label on Oct. 14, 2026 to include patients with high‑grade papillary‑only tumors. However, a $77.9 million non‑cash charge drove a net loss of $184.6 million, and the company missed revenue and EPS estimates, causing the shares to tumble 15‑18%.
Why it matters
The earnings miss and larger loss triggered a sharp stock decline, while the company’s cash of $334.3 million is projected to fund operations for just over four quarters, raising dilution concerns as it relies on additional financing. The FDA label expansion could broaden the drug’s market, but investors must weigh the near‑term liquidity risk against the growth potential.
Key facts
- 1Q3 2026 product revenue was $48.7 million, up 53% YoY. tradingview.com
- 2Nine‑month revenue reached $143.6 million, up 92% YoY. tradingview.com
- 3The FDA expanded ANKTIVA’s label on Oct. 14, 2026 to cover adults with BCG‑unresponsive non‑muscle‑invasive bladder cancer who have high‑grade papillary‑only tumors. 247wallst.com
- 4A $77.9 million non‑cash charge from fair‑value adjustments to a related‑party convertible note and warrant liabilities was recorded. 247wallst.com
- 5Net loss to common stockholders was $184.6 million for the quarter. blockonomi.com
- 6Cash, cash equivalents and marketable securities totaled $334.3 million at quarter‑end. investing.com
Open questions
- Reported Q3 revenue is given as $48.7 million and $48.84 million, a conflict on the same basis.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.